Back to top

Takeda Tracks Real World Safety of Ceprotin (TAK-662) in Rare Clotting Disorder

Takeda Pharmaceutical Company ($TAK) announced an update on their ongoing clinical study. Takeda’s new study tracks real world use of Ceprotin, als...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Takeda Pharmaceutical Co. (TAK)